Impact of MTX treatment according to IgG-NMO status
| IgG-NMO positive | IgG NMO- negative | p Value | |
|---|---|---|---|
| ARR | |||
| Whole cohort (N=46) | |||
| Baseline | 1.75 | 2 | NS |
| Year 1 | 0.41 | 0.26 | NS |
| Year 2 | 0.65 | 0.37 | 0.03 |
| Year 3 | 0.64 | 0.24 | 0.003 |
| Year 4 | 0.59 | 0.19 | 0.004 |
| Year 5 | 0.60 | 0.22 | 0.03 |
| NMO (N=26) | |||
| Baseline | 1.85 | 2.1 | NS |
| Year 1 | 0.23 | 0.23 | NS |
| Year 2 | 0.86 | 0.46 | 0.05 |
| Year 3 | 0.79 | 0.23 | 0.005 |
| Year 4 | 0.75 | 0.20 | 0.006 |
| Year 5 | 0.80 | 0.24 | 0.03 |
| EDSS | |||
| Baseline | 5.8 | 5.6 | NS |
| Year 1 | 4.7 | 4.4 | NS |
| Year 2 | 4.6 | 4.2 | NS |
| Year 3 | 5.1 | 4.4 | NS |
| Year 4 | 5.4 | 4.0 | NS |
| Year 5 | 5.0 | 4.4 | NS |
| MRI activity (%) | |||
| Baseline | 50 | 50 | NS |
| Year 1 | 17.4 | ‘4.8 | NS |
| Maintenance therapy after completion of MTX treatment (%) | 8.3 | 4.3 | NS |
ARR, annualised relapse rate; EDSS, expanded disability status scale; IgG, immunoglobulin G; MTX, mitoxantrone; NMO, neuromyelitis optica.